Caris Life Sciences stockCAI
Caris Life Sciences trades at $26.03, 28.7% below its 52-week high (Oct 28, 2026). The price is below its 50-day but above its 200-day average: a pullback within an uptrend. −3.5% year to date, −10.9% over 12 months (S&P 500 over the same period: +8.8%). Next earnings report: Mar 4, 2027.
- Market pulseCaris Life Sciences raises 2026 revenue guidance after Q3 revenue beats estimates
- Market pulseCaris Life Sciences posts Q3 2026 non-GAAP EPS $0.05 vs $0.03 consensus, raises 2026 revenue outlook to $1.04–$1.05 billion
- PR NewswireCaris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
The trigger was the quarterly report: EPS −38% year over year, 77.7% above the estimate.
All moves of the day →Ratings, candles, signals and the screener for CAI — after you log in
Open the terminalFrequently asked questions about Caris Life Sciences
What is the Caris Life Sciences stock price?
At the close on Nov 5, 2026: $26.03 (−21.64% on the day). 52-week high: $36.50 on Oct 28, 2026. During the session the price is updated with a 15-minute delay, after the close with the day's final figures.
When does Caris Life Sciences report earnings?
The next quarterly report is on Mar 4, 2027. Last quarter, earnings per share changed −38% year over year, revenue +27%.
Does Caris Life Sciences pay dividends?
No, Caris Life Sciences does not pay dividends.
Where does Caris Life Sciences trade and how to buy it?
Ticker CAI, exchange Nasdaq, listed since 2025. You can buy it through a broker with access to US exchanges.
Should I buy Caris Life Sciences now?
We do not give buy or sell advice. Ratings, the detailed chart and signals for CAI are in the terminal after you log in.